ropeginterferon alfa-2b

{
  "id": "MLC-T-ONC-007493",
  "term": "ropeginterferon alfa-2b",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with polycythemia vera (a disease in which too many red blood cells are made in the bone marrow). It is also being studied in the treatment of other conditions and some types of cancer. Ropeginterferon alfa-2b is a form of recombinant interferon alfa-2b that is made in the laboratory and linked to a substance called PEG, which makes the drug stay in the body longer. Ropeginterferon alfa-2b may lower the number of red blood cells made in the bone marrow. It is a type of cytokine and a type of immunomodulating agent. Also called Besremi.",
    "A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life."
  ],
  "synonyms": [
    "Besremi",
    "PEG-P-IFN-alpha-2b",
    "PEG-proline-interferon Alfa-2b",
    "PEG-P-IFN-alfa-2b"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ropeginterferon-alfa-2b/"
}